Top Markets
#1 GoPlus Security GoPlus Security +40.91%
#2 Tutorial Tutorial +21.27%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.85%
#4 Pons Pons +18.51%
#5 Status Status +14.44%
#6 SkyAI SkyAI +13.40%
#7 Verus Coin Verus Coin +13.11%
#8 Nillion Nillion +8.72%
#9 BankrCoin BankrCoin +8.66%
#10 Talus Network Talus Network +8.55%
Coin of the day
GoPlus Security GoPlus Security
Settings
Language
ENGLISH
Currency
USD
Theme
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
Rank in Stocks #33746
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Share Price
$0.11284557
Market Cap
$6.98M
Change (1 day)
0.00%
Change (1 year)
162.85%
Country
AU
Trade Vectus Biosystems Limited (VBS)

Category

Healthcare
Revenue for Vectus Biosystems Limited (VBS)
Revenue in Aug 2026 TTM: 0
According to Vectus Biosystems Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Vectus Biosystems Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE